← Library

Cognitive

Semax / Selank

Mixed / limited human dataInvestigational or unapprovedUnder editorial review

Synthetic peptides developed in Russia and studied for cognitive and anxiety-related effects.

This profile is still being checked by our editors. Treat the summary as unconfirmed until it is marked reviewed.

Where the evidence comes from

78 verified records from 6 countries. The number of studies or countries is not proof that Semax / Selank works or is safe.

6 human studies4 reviews68 lab, animal or other

Other: 3 · Animal study: 65 · Narrative review: 4 · Human clinical trial: 2 · Observational human study: 3 · Randomized clinical trial: 1

What is known

Editorial summary not yet written.

What remains uncertain

Editorial summary not yet written.

Conflicting findings

Editorial summary not yet written.

U.S. regulatory status (FDA)

Compound

Semax; Selank

Product or formulation

Nasal sprays (approved in Russia); research vials elsewhere

FDA status

Investigational or unapproved

FDA-approved branded drug

None

Approved indication

None

Metara availability (compounded formulation)

Research material (research use only)

Available through BioNex Peptides

Source

Last verified

September 27, 2026

Notes

Not FDA-approved. Approval in Russia does not imply U.S. approval.

Approval applies only to the exact finished drug, formulation and indication. A shared active ingredient does not make a compounded version, blend or other use FDA-approved. Pharmacy or research-material availability is not FDA approval.

International regulatory status

Kept separate from U.S. status. The regulator's country is not the same as where studies took place.

No sourced international decisions recorded yet.

Continue your research

These are two different pathways, not two ways to get the same thing. Neither changes the FDA status shown above.

Clinical care

Available through Metara Health

Explore clinician-guided care and available pharmacy options.

EXPLORE METARA HEALTH →

Research materials

Available through BioNex Peptides

Explore research-use materials, lot-specific analytical testing and research documentation.

EXPLORE BIONEX →

Limitations

Most human studies are small and published in Russian journals.

Human clinical evidence (6)

Editorially verified studyHuman clinical trialNA · UnknownLocation context: Italy2023-05-01

Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With Dyslexia

Bambino Gesù Hospital and Research Institute · ClinicalTrials.gov · NCT05832060

This registered human trial was designed to compare two forms of electrical brain stimulation with sham stimulation for improving reading skills in children and adolescents with dyslexia. Its status is unknown, and the abstract presents expected benefits and safety as hypotheses rather than results.

Original source →Via ClinicalTrials.gov · checked 2026-09-07
Editorially verified studyObservational human studyLocation context: Italy2022

Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models.

Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F · ACS chemical neuroscience · DOI 10.1073/pnas.95.11.6448

This lab study tested how Semax affected amyloid-beta clumping and copper interactions in artificial membrane models and laboratory assays, not in people. Semax prevented amyloid-beta–copper complexes from forming and showed anti-clumping and protective properties, especially when copper was present. The findings suggest that Semax inhibits amyloid fiber formation by interfering with these complexes.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyObservational human studyLocation context: Russia2020

Functional Connectomic Approach to Studying Selank and Semax Effects.

Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF · Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · DOI 10.1134/S001249662001007X

This human study used resting-state brain scans to examine Selank and Semax effects in healthy participants compared with placebo. Researchers identified shared and distinct effects on functional connectivity, meaning coordinated brain activity, between the right amygdala and the right temporal cortex.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyObservational human studyLocation context: Russia2018

Effects of Semax on the Default Mode Network of the Brain.

Lebedeva IS, Panikratova YR, Sokolov OY, Kupriyanov DA, Rumshiskaya AD, Kost NV, Myasoedov NF · Bulletin of experimental biology and medicine · DOI 10.1007/s10517-018-4234-3

This human study used resting-state brain scans to compare healthy volunteers receiving Semax or placebo. The Semax group showed a greater volume of the medial frontal component of the brain's default mode network than controls. The study demonstrated the location of Semax-related effects on this brain network.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyRandomized clinical trialClinical2015

[Optimization of the treatment of anxiety disorders with selank].

Medvedev VE, Tereshchenko ON, Kost NV, Ter-Israelyan AY, Gushanskaya EV, Chobanu IK, Sokolov OY, Myasoedov NF · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · DOI 10.17116/jnevro20151156133-40

This human study compared phenazepam alone with selank plus phenazepam in people with anxiety disorders. The combined treatment produced an earlier therapeutic effect on the HDRS rating scale and reduced several phenazepam side effects during treatment and after withdrawal. The authors reported a positive impact on quality of life.

Original source →Via PubMed · checked 2026-09-26
Editorially verified studyHuman clinical trialNA · CompletedLocation context: United States2012-11-16

Modulating Behavior in Humans by Entrainment With Rhythmic Transcranial Magnetic Stimulation

National Institute of Neurological Disorders and Stroke (NINDS) · ClinicalTrials.gov · NCT01747200

This completed human study investigated whether transcranial magnetic stimulation could alter brain rhythms and interfere with recognizing pictures of familiar objects in healthy adults. The abstract describes brain-wave monitoring and recognition tests, but reports no results.

Original source →Via ClinicalTrials.gov · checked 2026-09-07

Systematic & narrative reviews (4)

Editorially verified studyNarrative reviewLocation context: India2025

Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases.

Giri S, Chandra P · Neuropeptides · DOI 10.1016/j.npep.2025.102563

This review examined peptides and proteins, including Semax, in preclinical studies and early human trials of neurodegenerative diseases. It reports effects on oxidative stress, inflammation, cellular energy systems, and nerve-cell connections. The authors highlight potential protective benefits but emphasize delivery challenges and the need for further clinical validation.

Original source →Via PubMed · checked 2026-09-26
Editorially verified studyNarrative review2014

Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.

Charland SL, Stanek EJ · Pharmacotherapy · DOI 10.1002/phar.1368

This analysis used published human cardiovascular trial data to model the relationship between LDL cholesterol and coronary death or nonfatal heart attack. The best-fitting model projected diminishing reductions in these events as LDL cholesterol fell to lower levels. It studied cholesterol and statins, not the Semax peptide.

Original source →Via PubMed · checked 2026-09-26
Editorially verified studyNarrative review2008

[Evolution of the stress concept].

Sudakov KV · Vestnik Rossiiskoi akademii meditsinskikh nauk · PMID 19140465

This review discussed theories of emotional stress, brain signaling, and peptides including Semax; the abstract does not specify human or animal study populations. It describes these peptides as factors that increase resistance to stress and emphasizes individual differences in stress tolerance.

Original source →Via PubMed · checked 2026-09-26
Editorially verified studyNarrative reviewLocation context: Russia

Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress

· DOI 10.1023/a:1025988519919

This animal study compared Selank and related tuftsin-family peptides in male rats and mice exposed to a stressful conflict situation. The peptides showed positive emotional and anti-stress effects. Individual effects varied with the peptides' molecular structures or their breakdown products.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26

Laboratory, animal & other research (68)

Editorially verified studyOtherLocation context: Italy2025

Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing.

Tomasello MF, Di Rosa MC, Naletova I, Sciacca MFM, Giuffrida A, Maccarrone G, Attanasio F · Bioinorganic chemistry and applications · DOI 10.1039/c9mt00045c

This lab study examined Semax in copper–amyloid-beta reactions and cultured SH-SY5Y cells. Semax removed copper from amyloid-beta complexes, altered their chemical cycling, and reduced production of reactive oxygen molecules. The cell findings suggest that Semax has protective properties against oxidative stress caused by copper-driven amyloid-beta oxidation.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyAnimal studyPreclinical (animal)Location context: Russia2025-06-28

Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage

Filippenkov IB, Shpetko YY, Ales DA, Stavchansky VV, Denisova AE, Yuzhakov VV, Fomina NK, Gubsky LV, Andreeva LA, Myasoedov NF, Limborska SA, Dergunova LV · International journal of molecular sciences · DOI 10.3390/ijms26136256

This animal study examined how Semax and another ACTH-like peptide affected gene activity in rat brain regions after an experimentally induced stroke. Both peptides tended to normalize disrupted gene activity, but effects differed by brain region. The other peptide also worsened some gene-activity disturbances in the striatum, mainly involving inflammation.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyOtherLocation context: Russia2025

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

Radchenko AI, Kuzubova EV, Apostol AA, Mitkevich VA, Andreeva LA, Limborska SA, Stepenko YV, Shmigerova VS, Solin AV, Korokin MV, Pokrovskii MV, Myasoedov NF · Acta naturae · DOI 10.32607/actanaturae.27808

This animal study tested Semax and a derivative in genetically modified mice used as a model of Alzheimer's disease. Both peptides improved cognitive function in behavioral tests and reduced amyloid deposits in the cortex and hippocampus.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyAnimal studyLocation context: China2025

Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.

Liu R, Chen Y, Huang H, Li X, Lv J, Jiang L, Jiang H, Wu C, Chen W, Xu H, Zhu Z, Cai H · British journal of pharmacology · DOI 10.1111/bph.70122

This animal and lab study examined Semax in female mice with spinal cord injury and in a cell model of nerve inflammation. Semax improved functional recovery in mice and reduced oxidative stress and inflammatory cell death in the models. The findings linked these effects to opioid receptors and a pathway that removes molecular tags from proteins.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyAnimal studyPreclinical (animal)Location context: Russia2025-08-01

The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons

Kolbaev SN, Sharonova IN, Skrebitsky VG · Bulletin of experimental biology and medicine · DOI 10.1007/s10517-025-06501-z

This lab study examined Semax’s effects on calcium signals in nerve cells within rat brain slices. Semax increased the frequency of spontaneous calcium fluctuations in hippocampal cells but did not significantly affect acid-triggered calcium increases in cerebellar cells. The findings suggest its protective mechanism is not related to reducing calcium entry through acid-sensing channels in those cerebellar cells.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyAnimal studyPreclinical (animal)Location context: Russia2024-10-21

Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress

Inozemtseva LS, Yatsenko KA, Glazova NY, Kamensky AA, Myasoedov NF, Levitskaya NG, Grivennikov IA, Dolotov OV · European journal of pharmacology · DOI 10.1016/j.ejphar.2024.177068

This animal study tested Semax and Melanotan II in male rats exposed to chronic unpredictable stress. Both peptides reversed or reduced loss of pleasure-seeking behavior, suppressed weight gain, adrenal enlargement, and reductions in a brain protein involved in nerve-cell support. Neither peptide changed immobility in the forced-swim test.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26
Editorially verified studyAnimal studyPreclinical (animal)Location context: Russia2024

Changes of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides.

Filippenkov IB, Glazova NY, Sebentsova EA, Stavchansky VV, Andreeva LA, Myasoedov NF, Levitskaya NG, Limborska SA, Dergunova LV · Biochemistry. Biokhimiia · DOI 10.1134/S0006297924090104

This animal study examined gene activity in the frontal brain region of rats given Semax or a related ACTH-like peptide under normal conditions. Both peptides mainly reduced activity of immune-related genes. Differences between their effects involved genes linked to nerve signaling and ion-channel regulation.

Original source →Via PubMed · checked 2026-09-26
Editorially verified studyAnimal studyPreclinical (animal)Location context: Russia2022-10-01

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats

Konstantinopolsky MA, Chernyakova IV, Kolik LG · Bulletin of experimental biology and medicine · DOI 10.1007/s10517-022-05624-x

This animal study tested Selank in morphine-dependent rats whose withdrawal was triggered by naloxone. Selank reduced overall withdrawal signs, including convulsive reactions, drooping eyelids, and posture problems, and raised the threshold for responding to touch. Its effects were slightly weaker than those of diazepam.

Original source →Via BioNex Evolve (PubMed-indexed) · checked 2026-09-26

Browse worldwide evidence → · Search and filter all Semax / Selank studies →

Stay Current on Peptide Research

Get updates on newly published research, clinical trials, regulatory developments and major evidence updates tracked by Peptide Protocol Builder.

Research and educational updates only. Unsubscribe anytime.

Next steps

Clinical care

Available through Metara Health

EXPLORE METARA HEALTH →

Research materials

Available through BioNex Peptides

EXPLORE BIONEX →

Profile last reviewed September 26, 2026. Educational content only. Not medical advice, a dosing protocol or a treatment recommendation.